Clinical Commissioning Urgent Policy Statement: Cystic fibrosis modulator therapies access agreement for licensed mutations

Document first published:
Page updated:
Topic:
,
Publication type:

NHS England provides through an access agreement the cystic fibrosis modulator therapies: Ivacaftor; lumacaftor/ivacaftor; and tezacaftor/ivacaftor for patients in England as defined by their marketing authorisations. This updated policy includes access to the triple therapy elexacaftor/tezacaftor/ivacaftor according to the European marketing authorisation and other revisions to the market authorisations for these products since the policy was first published.